The FDA issued updated guidance for generic companies seeking to develop copycats of blockbuster GLP-1 receptor agonists such as Zepbound and Ozempic. The revisions address how generic developers should structure evidence generation for these widely used therapies. The agency’s move comes as more companies prepare obesity-drug follow-on strategies and as payers and clinicians anticipate broader access if generics gain authorization. Investors will watch whether the guidance clarifies bridging strategies that can accelerate development or tighten requirements for bioequivalence, clinical endpoints, and formulation stability. The update is likely to influence timelines for new filings and the competitive landscape for low-cost versions of branded weight-loss treatments.